BCL2L1 and metastatic melanoma: Complicating an antisense strategy, Bcl-2 expression may also be reduced in metastatic melanoma [119], and other antiapoptotic Bcl-2 proteins such as Mcl-1 or Bcl-xL may substitute for Bcl-2 [120].